RIGL EBITDA Growth
Rigel Pharmaceuticals Inc · EBITDA Growth
RIGL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-13.97%period ending
RIGL TTM EBITDA YoY % (28.64% → -13.97%)
Year-over-year change
High-resolution chart · PNG
RIGL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -13.9739% | |
| 170.945% | |
| 361.4268% | |
| 809.6356% | |
| 2,319.3706% | |
| 541.3243% | |
| 267.9053% | |
| 179.8085% | |
| 84.4126% | |
| 72.4423% | |
| 68.4766% | |
| 77.9469% | |
| 60.1045% | |
| 49.7509% | |
| -377.257% | |
| -773.4451% | |
| -2,574.6707% | |
| -994.1899% | |
| 59.2306% | |
| 65.5067% | |
| 87.4064% | |
| 73.0492% | |
| 57.9741% | |
| 44.5534% | |
| 59.9993% | |
| 58.1853% | |
| 7.8464% | |
| 53.6427% | |
| 37.746% | |
| 26.6808% | |
| 9.6853% | |
| -45.9858% | |
| -39.455% | |
| -41.7584% | |
| -25.5767% | |
| -14.8808% | |
| -36.6839% | |
| -24.3702% | |
| -25.2982% | |
| -0.0653% | |
| 32.8152% | |
| 41.4578% | |
| 43.4087% | |
| 29.3322% | |
| 13.9697% | |
| -2.216% | |
| -2.8403% | |
| 9.4153% | |
| 11.3525% | |
| 15.7726% | |
| 10.3436% | |
| 3.9847% | |
| -7.6283% | |
| -13.9186% | |
| -14.3794% | |
| -28.1699% | |
| -1,090.6548% | |
| -312.2969% | |
| -315.1551% | |
| -342.4225% | |
| 83.5021% | |
| 139.8257% | |
| 135.6026% | |
| 126.3001% | |
| 65.1096% | |
| 24.9353% | |
| 18.6674% | |
| 2.1298% | |
| -26.8415% | |
| -53.9184% | |
| -73.0415% | |
| -62.677% | |
| -54.1313% | |
| -77.1979% | |
| -87.809% | |
| -114.9152% | |
| -86.0485% | |
| -10.954% | |
| 10.9388% | |
| 32.2486% | |
| 32.6291% | |
| 15.0831% | |
| 14.2254% | |
| 0.4075% | |
| -16.1386% | |
| -21.8354% | |
| -44.7384% | |
| -55.953% | |
| -46.036% | |
| -40.5467% | |
| -20.704% | |
| -13.7379% | |
| -26.1713% | |
| -40.5064% | |
| -71.3752% | |
| 41.0048% | |
| 39.2267% | |
| 30.3071% | |
| 28.6375% |